• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Tharimmune Inc. filed SEC Form 8-K: Leadership Update

    5/9/25 4:56:54 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $THAR alert in real time by email
    false 0001861657 0001861657 2025-05-09 2025-05-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported) May 9, 2025

     

    THARIMMUNE, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41210   84-2642541
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (I. R. S. Employer
    Identification No.)

     

    1200 Route 22 East, Suite 2000

    Bridgewater, NJ 08807

    (Address of principal executive offices, including zip code)

     

    (908) 955-3140

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common stock, $0.0001 par value   THAR   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On May 9, 2025, the Board of Directors (the “Board”) of Tharimmune, Inc. (the “Company”) appointed Vincent LoPriore, a director of the Company, as Executive Chairman of the Board, effective immediately. Mr. LoPriore shall replace Randy Milby who served as Chairman of the Board.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: May 9, 2025 Tharimmune, Inc.
       
      /s/ Randy Milby
      Randy Milby
      Chief Executive Officer

     

     

     

    Get the next $THAR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $THAR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $THAR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

      BRIDGEWATER, NJ / ACCESSWIRE / December 16, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced plans for initiating a Phase 2 study evaluating TH104 in patients suffering from moderate-to-severe pruritus (severe itching) associated with primary biliary cholangitis (PBC), a rare and chronic liver disease, and also provided a corporate update. The launch of this clinical trial, expected in 2025, follows favorable results from Tharimmune's Phase 1 study with TH104, recent regulatory feedback from the European Medicines Agency (EMA) and the U.S. Food and Dr

      12/16/24 8:00:00 AM ET
      $THAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

      BRIDGEWATER, NEW JERSEY / ACCESSWIRE / December 6, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced it has entered into a securities purchase agreement to raise gross proceeds of approximately $2.02 million through a private placement.The agreement includes the issuance of 961,446 shares of common stock (or common stock equivalents) and warrants to purchase up to an additional 480,723 shares of common stock. Each share (or common stock equivalent) is priced at $2.10 and is accompanied by a warrant. The warrants will have an exercise price of $2.031 pe

      12/6/24 4:15:00 PM ET
      $THAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

      Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected treatment-emergent adverse eventsPhase 2 preliminary data for chronic pruritus in primary biliary cholangitis expected in 2025BRIDGEWATER, NJ / ACCESSWIRE / November 18, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, presented new TH104 clinical data at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024, underway in San Diego from November 15-19. The Phase 1 trial was a single-dose, single-center, ope

      11/18/24 8:00:00 AM ET
      $THAR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THAR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Tharimmune Inc.

      10-Q - Tharimmune, Inc. (0001861657) (Filer)

      5/12/25 8:00:49 AM ET
      $THAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tharimmune Inc. filed SEC Form 8-K: Leadership Update

      8-K - Tharimmune, Inc. (0001861657) (Filer)

      5/9/25 4:56:54 PM ET
      $THAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Tharimmune Inc.

      DEFA14A - Tharimmune, Inc. (0001861657) (Filer)

      5/2/25 5:07:48 PM ET
      $THAR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THAR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Parikh Sanam bought $1,001 worth of shares (770 units at $1.30) (SEC Form 4)

      4 - Tharimmune, Inc. (0001861657) (Issuer)

      5/16/25 4:15:32 PM ET
      $THAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Milby Randy bought $9,752 worth of shares (4,600 units at $2.12), increasing direct ownership by 36% to 17,534 units (SEC Form 4)

      4 - Tharimmune, Inc. (0001861657) (Issuer)

      12/20/24 8:00:31 PM ET
      $THAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Appajosyula Sireesh bought $10,096 worth of shares (5,000 units at $2.02), increasing direct ownership by 87% to 10,758 units (SEC Form 4)

      4 - Tharimmune, Inc. (0001861657) (Issuer)

      11/13/24 5:06:05 PM ET
      $THAR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THAR
    Leadership Updates

    Live Leadership Updates

    See more
    • Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

      BRIDGEWATER, NJ / ACCESSWIRE / December 16, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced plans for initiating a Phase 2 study evaluating TH104 in patients suffering from moderate-to-severe pruritus (severe itching) associated with primary biliary cholangitis (PBC), a rare and chronic liver disease, and also provided a corporate update. The launch of this clinical trial, expected in 2025, follows favorable results from Tharimmune's Phase 1 study with TH104, recent regulatory feedback from the European Medicines Agency (EMA) and the U.S. Food and Dr

      12/16/24 8:00:00 AM ET
      $THAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

      BRIDGEWATER, NJ / ACCESSWIRE / July 22, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, today announced the appointment of David Jones, Professor of Liver Immunology at Newcastle University in England, to its Scientific Advisory Board (SAB).Prof. Jones has earned an international reputation for his work in autoimmune liver disease. He leads the UK-PBC research consortium (MRC Stratified Medicine), which has the world's largest cohort of fully phenotyped primary biliary cholangitis/cirrhosis (PBC) patients. His areas of expertise include stratified the

      7/22/24 8:30:00 AM ET
      $THAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

      BRIDGEWATER, NJ / ACCESSWIRE / July 17, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces the appointment of David H. Clarke as a Strategic Advisor to the Company's executive management team."Tharimmune is pleased to have David join in an advisory capacity," stated Randy Milby, CEO of Tharimmune. "We believe his wide-ranging accomplishments and business insight will meaningfully strengthen our organization. In particular, we expect that his understanding of publicly traded company operations coupled with his leadership skills will provide stra

      7/17/24 8:30:00 AM ET
      $THAR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THAR
    Financials

    Live finance-specific insights

    See more
    • Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

      BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE / September 16, 2024 /Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that it has entered into a definitive agreement with Intract Pharma to exclusively license INT-023/TH023, an oral anti-tumor necrosis factor-alpha (TNF-α) monoclonal antibody, infliximab. This strategic partnership aims to expand Tharimmune's therapeutic pipeline and reinforce its commitment to pioneering novel treatments for autoimmune diseases.Under the terms of the agreement, Tharimmune licensed global development and commercia

      9/16/24 7:00:00 AM ET
      $THAR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THAR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Parikh Sanam bought $1,001 worth of shares (770 units at $1.30) (SEC Form 4)

      4 - Tharimmune, Inc. (0001861657) (Issuer)

      5/16/25 4:15:32 PM ET
      $THAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Kim Dong

      3 - Tharimmune, Inc. (0001861657) (Issuer)

      3/27/25 7:00:04 PM ET
      $THAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CEO Milby Randy

      4 - Tharimmune, Inc. (0001861657) (Issuer)

      1/14/25 4:47:22 PM ET
      $THAR
      Biotechnology: Pharmaceutical Preparations
      Health Care